Crucell « Terug naar discussie overzicht

J&J deal. Een poging tot analyse.

106 Posts, Pagina: « 1 2 3 4 5 6 | Laatste

Omlaag ↓

flosz 13 oktober 2009 22:21

quote:
Ronald_uit_030 schreef:
[quote=flosz]
[quote=Ronald_uit_030]

En Flosz, waarom haal jij die optie transacties van het MT van Crucell aan? Dat was toch volledig legaal?

Als je niet op de hoogte bent van wat geoorloofd is en wat niet, dan is al gauw elk bericht wat je niet aanstaat meteen een vorm van "manipulatie".....

Achterdocht komt vaak voort uit onwetendheid.

[/quote]

Om aan te geven dat dit geen CRXL-schandaaltje was maar valse berichtgeving en inzake QV: frauduleuze berichtgeving.

Achterdocht komt soms voort uit onwetendheid, gezonde achterdocht komt regelmatig voort uit ervaring imo.
"Leer van je fouten, nog beter: leer van de fouten van een ander"!(Quote Frenky Tornado).

[/quote]

Je gaat toch niet reageren op onbevestigde geruchten?

Maar ik begrijp wel dat iemand die dat wel doet, zich gemanipuleerd voelt. Als het gerucht inderdaad niet waar blijkt te zijn, tsja, dan ben je genaaid.

En dan moet je inderdaad nog van veel fouten leren.

Komop zeg.

Ik begrijp dat je er niets van begrepen hebt!
*********************

@ Dirk: Frenky is fietskampioen olé, olé, olé, oléééééé' & schoenvreetspecialist.

harvester 13 oktober 2009 23:03

svp weer terug naar het onderwerp.

J+J deal.

Met de cijfers van J+J aardig wat publiciteit voor Crucell.

Motley schrijft over J+J dat de krimp in de pharmatak over een paar jaar opgevangen moet worden door onder meer de deal met Crucell.

Dat is een mooie uitdaging en dat betekent dat er voor de andere 82% aandeelhouders volgens J+J ook aardig wat in het vat zit. Horen wij dat niet alleen meer van het Crucell MT.

Nog 21 dagen en dan weten wij wat het 3e kwartaal opgeleverd heeft en misschien weer wat meer over de J+J deal++

flosz 13 oktober 2009 23:13

quote:
harvester schreef:
svp weer terug naar het onderwerp.

J+J deal.

Met de cijfers van J+J aardig wat publiciteit voor Crucell.

Motley schrijft over J+J dat de krimp in de pharmatak over een paar jaar opgevangen moet worden door onder meer de deal met Crucell.

Terugkoppeling naar het art. uit je post:
www.iex.nl/forum/topic.asp?forum=228&...

harrysnel 2 juni 2010 12:01

Centocor Ortho Biotech Inc. Acquires RespiVert LTD., Strengthens Pulmonary Focus

Acquisition Bolsters Pulmonary Portfolio and Capabilities, Accessing Promising Pipeline of First-in-Class Compounds and Renowned Team of Respiratory Scientists

Horsham, Pa., June 1, 2010 - Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF). The clinical development of RV-568 and RV-1088 will be led by RespiVert in collaboration with scientists at Centocor Research and Development, Inc. The company is not disclosing financial terms.

"The RespiVert compounds offer the potential for a new class of medicines for patients with severe lung disease who are insensitive to inhaled corticosteroids," said Susan Dillon, Ph.D., Global Therapeutic Area Head, Immunology, Centocor Research and Development, Inc. "The addition of RespiVert's expert scientific team and discovery platforms for inhaled medicines strengthens our capabilities and further builds our pipeline of novel oral and biologic therapies for serious pulmonary diseases."

With the acquisition of RespiVert, Centocor Ortho Biotech gains a portfolio of first-in-class, early-stage inhaled treatments for serious lung diseases. RespiVert will continue to maintain its research and discovery presence in London from the Imperial BioIncubator, which is based at the campus of Imperial College London. RespiVert employees will continue to lead ongoing research and drug discovery efforts.

Dr. Garth Rapeport, Chief Executive Officer of RespiVert, who is remaining with RespiVert following the acquisition, said, "We believe that our focused discovery efforts in pulmonary disease offer a unique opportunity to bring completely new treatment options to patients who suffer from severe, chronic respiratory diseases including Chronic Obstructive Pulmonary Disease, severe asthma and Cystic Fibrosis."

About Asthma, COPD, and CF

Severe or uncontrolled asthma is associated with significant morbidity, resulting in missed work and school days, and substantial limitation of activity, adversely impacting quality of life in asthmatics. Severe asthma represents a particular societal burden, with sources suggesting that half of the total cost of asthma in the United States is attributable to severe disease. Asthma is the cause of over 4,000 deaths each year in the U.S. and over 12,000 in Europe.

COPD is an umbrella term for a group of lung diseases which include chronic bronchitis, emphysema and small airways disease. COPD is a serious, chronic disorder characterized by a slowly progressive decline in lung function with symptoms such as chronic cough and dyspnea significantly impacting quality of life. COPD is estimated to cause 130,000 deaths per year in the U.S.

CF is an inherited life-threatening disease involving a genetic mutation that disrupts the cystic fibrosis transmembrane regulator (CFTR) protein, resulting in poorly hydrated, thickened mucous secretions in the lungs and digestive tract. Due to these changes, the lungs of individuals with cystic fibrosis are colonized and infected by bacteria from an early age. This leads to progressive and severe lung inflammation which is difficult to treat.

About Centocor Ortho Biotech Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Inc. were consolidated in late 2008, and was renamed Centocor Ortho Biotech Inc. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and healthcare professionals have access to the latest treatment information, support services and quality care. For more information about Centocor Ortho Biotech, visit www.CentocorOrthoBiotech.com. Centocor Ortho Biotech Inc. and Centocor Research and Development Inc. are wholly-owned subsidiaries of Johnson & Johnson.

About RespiVert

RespiVert is a small molecule drug discovery company working towards the identification of new treatments for patients with Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF) and severe asthma. The more severe forms of these diseases are poorly responsive to existing therapies such as inhaled corticosteroids and new disease modifying treatments are urgently required. RespiVert has been financed by Advent Venture Partners, Fidelity Biosciences, Imperial Innovations and SV Life Sciences.

www.investor.jnj.com/releasedetail.cf...

Overname sluit m.i. aan op de samenwerking tussen Crucell en Calmune en de focus van J&J op pulmonary diseases.
www.iex.nl/forum/topic.asp?forum=228&...

Ook relatie met Galapagos/Tibotec
www.respivert.com/board-rudi-pauwels....

aossa 4 juni 2010 15:23

AVA 4/06/2010:

Bovenop gekende financiele deals en milestones betaalt J&J ook nog enorm voor gepresteerd werk door R&D.

aossa 4 juni 2010 15:51

quote:
aossa schreef:
AVA 4/06/2010:

Bovenop gekende financiele deals en milestones betaalt J&J ook nog enorm voor gepresteerd werk door R&D.

Wordt geboekt als 'funding'...

106 Posts, Pagina: « 1 2 3 4 5 6 | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 913,61 -5,65 -0,61% 16:25


Germany40^	22.822,40	-0,77%
BEL 20	4.480,07	-0,17%
Europe50^	5.414,94	-0,66%
US30^	41.716,90	-0,62%
Nasd100^	19.520,60	-0,85%
US500^	5.623,83	-0,72%
Japan225^	37.427,30	-0,71%
Gold spot	3.014,23	-1,04%
EUR/USD	1,0828	-0,27%
WTI	68,15	-0,26%